Efficacy and Safety of Brodalumab In Patients With Moderate To Severe Plaque Psoriasis: Results of AMAGINE-1, a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study

被引：0
|
作者：
Papp, K. [1 ]
Reich, K. [2 ]
Blauvelt, A. [3 ]
Baran, W. [4 ]
Bolduc, C. [5 ,6 ]
Toth, D. [7 ,8 ]
Gottlieb, A. B. [9 ]
Thaci, D. [10 ]
Li, J. [11 ]
Nirula, A. [11 ]
机构：
[1] Prob Med Res, Waterloo, ON, Canada
[2] Dermatologikum Hamburg, Hamburg, Germany
[3] Oregon Med Res Ctr, Portland, OR USA
[4] Wroclaw Med Univ, Wroclaw, Poland
[5] Univ Montreal, Montreal, PQ, Canada
[6] Innovaderm Res, Montreal, PQ, Canada
[7] XLR8 Med Res, Windsor, ON, Canada
[8] Prob Med Res, Windsor, ON, Canada
[9] Tufts Med Ctr, Boston, MA USA
[10] Med Univ Lubeck, D-23538 Lubeck, Germany
[11] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
JOURNAL OF INVESTIGATIVE DERMATOLOGY | 2015年 / 135卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
043
引用
收藏
页码：S8 / S8
页数：1
相关论文
共 50 条
  • [41] Improvements in patient-reported outcomes (PROs) among moderate to severe plaque psoriasis patients treated with brodalumab: Results from AMAGINE-1
    Strober, Bruce
    Gordon, Kenneth
    Augustin, Matthias
    Viswanathan, Hema
    Klekotka, Paul
    Milmont, Cassandra
    Kricorian, Gregory
    Harrison, David
    Pinto, Lionel
    Nirula, Ajay
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB256 - AB256
  • [42] A multicentre, randomized, double-blind, placebo-controlled Phase II study to evaluate the efficacy and safety of individual dose regimens of HB0017 in patients with moderate-to-severe plaque psoriasis
    Zhang, Furen
    Qiao, Jianjun
    Ding, Yangfeng
    Zhang, Chunlei
    Xiao, Rong
    Liu, Xiaoyan
    Ma, Chi
    Ge, Cuizhu
    Li, Benke
    Cai, Ye
    Ma, Xiuqiang
    Zhu, Xiangyang
    Zhang, Jianzhong
    BRITISH JOURNAL OF DERMATOLOGY, 2024, 191
  • [43] Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study
    Ohtsuki, Mamitaro
    Kubo, Hiroshi
    Morishima, Hitomi
    Goto, Ryosuke
    Zheng, Richuan
    Nakagawa, Hidemi
    JOURNAL OF DERMATOLOGY, 2018, 45 (09): : 1053 - 1062
  • [44] Efficacy and safety of apremilast in subjects with moderate to severe plaque psoriasis: results from a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison study
    Papp, K. A.
    Kaufmann, R.
    Thaci, D.
    Hu, C.
    Sutherland, D.
    Rohane, P.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 (03) : e376 - e383
  • [45] Relationship of serum vitamin D with psoriasis severity and adalimumab response in Chinese patients with moderate to severe plaque psoriasis from a phase 3, randomized, placebo-controlled, double-blind study
    Zhang, Jianzhong
    Geng, Ziqian
    Teixeira, Henrique D.
    Okun, Martin M.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2016, 74 (05) : AB267 - AB267
  • [46] Efficacy and Safety of Combination Acitretin and Pioglitazone Therapy in Patients With Moderate to Severe Chronic Plaque-Type Psoriasis A Randomized, Double-blind, Placebo-Controlled Clinical Trial
    Mittal, Rajan
    Malhotra, Samir
    Pandhi, Promila
    Kaur, Inderjeet
    Dogra, Sunil
    ARCHIVES OF DERMATOLOGY, 2009, 145 (04) : 387 - 393
  • [47] Efficacy and Safety of Adalimumab among Patients with Moderate to Severe Psoriasis with Co-Morbidities Subanalysis of Results from a Randomized, Double-Blind, Placebo-Controlled, Phase III Trial
    Kimball, Alexa B.
    Bensimon, Arielle G.
    Guerin, Annie
    Yu, Andrew P.
    Wu, Eric Q.
    Okun, Martin M.
    Bao, Yanjun
    Gupta, Shiraz R.
    Mulani, Parvez M.
    AMERICAN JOURNAL OF CLINICAL DERMATOLOGY, 2011, 12 (01) : 51 - 62
  • [48] Secukinumab treatment shows a neutral effect on the lipid profile of patients with moderate to severe plaque psoriasis: Results from a randomized, double-blind, placebo-controlled, phase II study
    Mrowietz, Ulrich
    Qureshi, Abrar
    Escrig, Cesar
    Richards, Hanno
    Thurston, Helen
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2013, 68 (04) : AB212 - AB212
  • [49] Apremilast for the treatment of moderate-to-severe palmoplantar psoriasis: results from a double-blind, placebo-controlled, randomized study
    Bissonnette, R.
    Haydey, R.
    Rosoph, L. A.
    Lynde, C. W.
    Bukhalo, M.
    Fowler, J. F.
    Delorme, I.
    Gagne-Henley, A.
    Gooderham, M.
    Poulin, Y.
    Barber, K.
    Jenkin, P.
    Landells, I.
    Pariser, D. M.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2018, 32 (03) : 403 - 410
  • [50] The efficacy and safety of dupilumab in Chinese patients with moderate-to-severe atopic dermatitis: a randomized, double-blind, placebo-controlled study
    Zhao, Y.
    Wu, L.
    Lu, Q.
    Gao, X.
    Zhu, X.
    Yao, X.
    Li, L.
    Li, W.
    Ding, Y.
    Song, Z.
    Liu, L.
    Dang, N.
    Zhang, C.
    Liu, X.
    Gu, J.
    Wang, J.
    Geng, S.
    Liu, Q.
    Guo, Y.
    Dong, L.
    Su, H.
    Bai, L.
    O'Malley, J. T.
    Luo, J.
    Laws, E.
    Mannent, L.
    Ruddy, M.
    Amin, N.
    Bansal, A.
    Ota, T.
    Wang, M.
    Zhang, J.
    BRITISH JOURNAL OF DERMATOLOGY, 2022, 186 (04) : 633 - 641
12345